Resmed Inc. Stock
Price
Target price
€211.00
€211.00
-4.400%
-9.7
-4.400%
€259.74
10:33 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Resmed Inc. Stock
Heavy losses for Resmed Inc. today as the stock fell by -€9.700 (-4.400%).
With 21 Buy predictions and not a single Sell prediction Resmed Inc. is an absolute favorite of our community.
With a target price of 259 € there is a positive potential of 22.75% for Resmed Inc. compared to the current price of 211.0 €.
Pros and Cons of Resmed Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | -4.400% | 1.331% | 3.421% | -6.443% | -0.720% | -0.249% | 25.398% |
| Veeva Systems A | 0.100% | -2.407% | -16.139% | -4.082% | 1.772% | 13.117% | -10.900% |
| Thermo Fisher Scientific Inc. | -0.200% | -0.059% | 5.986% | 1.695% | 2.113% | -5.293% | 30.777% |
| Waters Corp. | 0.170% | 2.689% | 18.323% | -4.330% | -1.209% | 5.527% | 80.154% |
Comments
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Morgan Stanley from $298.00 to $304.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
ResMed: A Mixed Bag for Investors Amid Rising Competition
Explore the exciting world of ResMed (NYSE: RMD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential